Homepage > Company > Media > Pharma News > 2018 > Israeli co PolyPid files for $86m Nasdaq IPO

Israeli co PolyPid files for $86m Nasdaq IPO

PolyPid is a clinical-stage pharmaceutical company with an initial focus on antibiotics for the prevention and treatment of post-surgical site infections.

Israeli therapeutics company PolyPid Ltd. has filed a prospectus to raise $86 million on Nasdaq. The company did not disclose a company value but market sources estimate it at $300-400 million after money.

Based in Petah Tikva, PolyPid is a clinical-stage pharmaceutical company with an initial focus on antibiotics for the prevention and treatment of post-surgical site infections.

The company first filed in October 2014 to raise $20 million in an IPO at a company value of $80 million before money but withdrew the prospectus in 2015 and in 2016 received a private investment of $22 million instead.

PolyPid's main shareholders include Morris Kahn (18.3%), Shavit Capital (9.1%), Xenia Venture Capital Ltd. (TASE:XENA) (6.1%) and investors including Leon Recanat, Haim Hurvitz, and Eitan Kyiet.

Published by Globes [online], Israel business news - www.globes-online.com - on February 11, 2018

http://www.globes.co.il/en/

Read also

EC approves AstraZeneca’s Fasenra for EGPA treatment

The European Commission (EC) has approved AstraZeneca‘s Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangii...

Genprex reports positive preclinical gene therapy data

Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-...

Astellas withdraws Europe ACP application for AMD treatment

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...